Skip to content

Study · Not a test of the peptide alone · 2005

5 results

Properties of pramlintide and insulin upon mixing.

Weyer C, Fineman MS, Strobel S, Shen L, Data J, Kolterman OG, Sylvestri MF

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists1 Apr 2005Cited by 29 (Europe PMC)

PMID15821274 (opens in a new tab)DOI10.1093/ajhp/62.8.816 (opens in a new tab)PepBankPUB-15821274
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 01HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialPharmacokinetics

    In type 1 diabetes, mixtures containing pramlintide and insulin produced serum free insulin AUC comparable to separate injections.

    In plain wordsIn type 1 diabetes, mixing pramlintide and insulin gave similar overall free insulin exposure to separate injections.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeSerum free insulin AUC
    Study

    n = 51

    Comparator
    Separate injections of pramlintide and insulin
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    All treatments involving mixtures were comparable to separate injections with respect to the area under the concentration-versus-time curve (AUC) and the maximum concentration (Cmax) of serum free insulin.
    3 context sentences
    Summary · context
    In two randomized, open-label, placebo-controlled, five-period-crossover studies, patients with type 1 DM received preprandial injections of pramlintide, short-acting insulin, and long-acting insulin administered either by separate injections or after mixing in various combinations.
    Summary · context
    Serum free insulin and plasma glucose concentrations were measured for 10 hours and plasma pramlintide concentrations for 5 hours after injection.
    Summary · context
    Blood samples were collected from a total of 51 patients.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 02HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialPharmacokinetics

    In type 1 diabetes, mixtures containing pramlintide and insulin produced free insulin Cmax comparable to separate injections.

    In plain wordsIn type 1 diabetes, mixing pramlintide and insulin gave similar peak free insulin levels to separate injections.

    Peptide
    Pramlintide (Symlin)
    Outcome
    No significant changeSerum free insulin Cmax
    Study

    n = 51

    Comparator
    Separate injections of pramlintide and insulin
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    All treatments involving mixtures were comparable to separate injections with respect to the area under the concentration-versus-time curve (AUC) and the maximum concentration (Cmax) of serum free insulin.
    3 context sentences
    Summary · context
    In two randomized, open-label, placebo-controlled, five-period-crossover studies, patients with type 1 DM received preprandial injections of pramlintide, short-acting insulin, and long-acting insulin administered either by separate injections or after mixing in various combinations.
    Summary · context
    Serum free insulin and plasma glucose concentrations were measured for 10 hours and plasma pramlintide concentrations for 5 hours after injection.
    Summary · context
    Blood samples were collected from a total of 51 patients.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  3. 03HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialPharmacokinetics

    In type 1 diabetes, mixing pramlintide with insulin produced some minor differences in pramlintide AUC and Cmax versus separate injections.

    In plain wordsIn type 1 diabetes, mixing pramlintide with insulin gave minor differences in overall and peak pramlintide levels versus separate injections.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Direction not reportedPramlintide AUC and Cmax
    Study

    n = 51

    Comparator
    Separate injections of pramlintide and insulin
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    There were some minor differences in the AUC and Cmax of pramlintide.
    3 context sentences
    Summary · context
    In two randomized, open-label, placebo-controlled, five-period-crossover studies, patients with type 1 DM received preprandial injections of pramlintide, short-acting insulin, and long-acting insulin administered either by separate injections or after mixing in various combinations.
    Summary · context
    Serum free insulin and plasma glucose concentrations were measured for 10 hours and plasma pramlintide concentrations for 5 hours after injection.
    Summary · context
    Blood samples were collected from a total of 51 patients.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  4. 04HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome

    In type 1 diabetes studies of pramlintide and insulin mixing, no injection-site reactions occurred.

    In plain wordsIn type 1 diabetes studies of pramlintide and insulin mixing, no injection-site reactions occurred.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableInjection-site reactions
    Study

    n = 51

    Outcome group
    Adverse events · Skin and wound

    Source sentences

    Summary
    No injection-site reactions or other unexpected adverse events were observed.
    3 context sentences
    Summary · context
    In two randomized, open-label, placebo-controlled, five-period-crossover studies, patients with type 1 DM received preprandial injections of pramlintide, short-acting insulin, and long-acting insulin administered either by separate injections or after mixing in various combinations.
    Summary · context
    Serum free insulin and plasma glucose concentrations were measured for 10 hours and plasma pramlintide concentrations for 5 hours after injection.
    Summary · context
    Blood samples were collected from a total of 51 patients.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  5. 05HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome

    In type 1 diabetes studies of pramlintide and insulin mixing, no other unexpected adverse events occurred.

    In plain wordsIn type 1 diabetes studies of pramlintide and insulin mixing, no other unexpected adverse events occurred.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableUnexpected adverse events
    Study

    n = 51

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    No injection-site reactions or other unexpected adverse events were observed.
    3 context sentences
    Summary · context
    In two randomized, open-label, placebo-controlled, five-period-crossover studies, patients with type 1 DM received preprandial injections of pramlintide, short-acting insulin, and long-acting insulin administered either by separate injections or after mixing in various combinations.
    Summary · context
    Serum free insulin and plasma glucose concentrations were measured for 10 hours and plasma pramlintide concentrations for 5 hours after injection.
    Summary · context
    Blood samples were collected from a total of 51 patients.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.